1. Search Result
Search Result
Results for "

peptide-1

" in MedChemExpress (MCE) Product Catalog:

183

Inhibitors & Agonists

4

Fluorescent Dye

5

Biochemical Assay Reagents

180

Peptides

1

Inhibitory Antibodies

7

Natural
Products

9

Recombinant Proteins

4

Isotope-Labeled Compounds

1

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Area
  • HY-P0122B

    Peptides Cancer
    iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers agents deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity [1].
  • HY-P3756

    EMP-1

    Peptides Inflammation/Immunology
    EPO mimetic peptide-1 (EMP-1), a 20 amino acid peptide. EPO mimetic peptide-1 stimulates cell proliferation, affects cell cycle and induces the production of reticulocytes in vivo [1].
  • HY-P10383

    Peptides Infection
    SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment [1].
  • HY-P10383A

    Peptides Infection
    SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment [1].
  • HY-P3712

    Peptides Cardiovascular Disease Neurological Disease
    Cardioexcitatory peptide 1 is a cardioexcitatory neuropeptide, can be isolated from Achatina atria. Cardioexcitatory peptide 1 has potent cardio-excitatory action on the hearts and also modifies the motility of muscular tissues and neural activities [1].
  • HY-P3414

    Peptides Neurological Disease
    Proteasome-activating peptide 1 is a peptide, which increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis [1].
  • HY-P2547

    Src Others
    Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay [1].
  • HY-P3414A
    Proteasome-activating peptide 1 TFA
    1 Publications Verification

    Proteasome Neurological Disease
    Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis [1].
  • HY-P1805

    Calmodulin Neurological Disease
    Calmodulin Binding Peptide 1 is a high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase (MLCK peptide), which strongly inhibits IP3-induced Ca 2+ release [1].
  • HY-P0277

    CAP1; CEA peptide

    Peptides Cancer
    Carcinoembryonic antigen peptide 1 (CAP1) is a tumor marker in lung cancer.
  • HY-P1758

    IRRP1

    IFNAR Infection
    IFN-α Receptor Recognition Peptide 1 is a peptide of IFN-α associated with receptor interactions [1].
  • HY-P3623

    Fluorescent Dye Others
    Biotin-Glucagon-Like Peptide 1 (7-36) amide, human is a biologically active peptide. Biotin-Glucagon-Like Peptide 1 (7-36) amide, human can be used for the research of various biochemical studies.
  • HY-P1145

    HuGLP-1

    GCGR Metabolic Disease
    Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.
  • HY-P1145A

    HuGLP-1 TFA

    GCGR Metabolic Disease
    Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.
  • HY-P2535

    GLP Receptor Metabolic Disease
    Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human is an C-terminal-labelled biotinylated GLP-1 (7-36) amide.
  • HY-P5815

    Glucagon-like peptide 1 (1-36) amide (human, rat)

    GLP Receptor GCGR Metabolic Disease
    GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells [1].
  • HY-P5815A

    Glucagon-like peptide 1 (1-36) amide (human, rat) (TFA)

    GLP Receptor GCGR Metabolic Disease
    GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells [1].
  • HY-P3586

    Hunter-killer peptide ao; Prohibitin-targeting peptide 1; prohibitin-TP01; Adipotide

    Apoptosis Cancer
    HKPao (Hunter-killer peptide ao) is a biologically active peptide. HKPao (Hunter-killer peptide ao) has anti-obesity and anti-tumor pro-apoptotic activity to cause release of cytochrome c from vesicles [1].
  • HY-P0120
    Dulaglutide
    1 Publications Verification

    LY2189265

    GCGR Metabolic Disease
    Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) [1] .
  • HY-P3542

    GCGR Metabolic Disease
    Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal [1].
  • HY-P3506

    LY3437943

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity [1].
  • HY-P3506B

    LY3437943 acetate

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity [1].
  • HY-P3539

    GCGR Neurological Disease Endocrinology
    Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis [1] .
  • HY-P3506A

    LY3437943 TFA

    GLP Receptor GCGR Metabolic Disease
    Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity [1].
  • HY-P0054
    GLP-1(7-36), amide acetate
    5+ Cited Publications

    Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate

    GCGR Metabolic Disease
    GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
  • HY-P0054A

    Glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide

    GCGR Metabolic Disease
    GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.
  • HY-P0014
    Liraglutide
    10+ Cited Publications

    GCGR GLP Receptor Metabolic Disease
    Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
  • HY-108795A

    GLP-1-Gly8 TFA; GLP-1 (7-36) analog TFA

    GLP Receptor Metabolic Disease
    Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies [1] .
  • HY-108795

    GLP-1-Gly8; GLP-1 (7-36) analog

    GLP Receptor Metabolic Disease
    Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies [1] .
  • HY-13443
    Exendin-4
    Maximum Cited Publications
    39 Publications Verification

    Exenatide

    GCGR Metabolic Disease
    Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-13443A
    Exendin-4 acetate
    Maximum Cited Publications
    39 Publications Verification

    Exenatide acetate

    GCGR Metabolic Disease
    Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-P3491

    PEX 168

    GLP Receptor Metabolic Disease
    Pegloxenatide is a glucagon-like peptide-1 receptor (GLP-1 RA) agonist. Pegloxenatide can be used for type 2 diabetes research [1].
  • HY-P0119A
    Lixisenatide acetate
    1 Publications Verification

    GCGR Metabolic Disease
    Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).
  • HY-P4407

    Peptides Metabolic Disease
    (D-Asn28)-Exenatide is an Exenatide (HY-13443) impurity. Exenatide is a long-acting glucagon-like peptide-1 receptor agonist [1].
  • HY-P4410

    Peptides Metabolic Disease
    (D-Asp28)-Exenatide is an Exenatide (HY-13443) impurity. Exenatide is a long-acting glucagon-like peptide-1 receptor agonist [1].
  • HY-103303

    Peptides Metabolic Disease
    CRSP-1 is short for calcitonin receptor-stimulating peptide-1. CRSP-1 inhibits osteoclast formation by inhibiting the formation and activity of multinucleated osteoclast [1].
  • HY-114118
    Semaglutide
    3 Publications Verification

    GCGR Metabolic Disease
    Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
  • HY-P4858

    GSK-3 Cancer
    C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer [1].
  • HY-P0054B
    GLP-1(7-36), amide TFA
    5+ Cited Publications

    Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA

    GCGR Metabolic Disease
    GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells [1].
  • HY-114118A
    Semaglutide TFA
    3 Publications Verification

    GCGR Metabolic Disease
    Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.
  • HY-P0014R

    GCGR GLP Receptor Metabolic Disease
    Liraglutide (Standard) is the analytical standard of Liraglutide. This product is intended for research and analytical applications. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
  • HY-P10269

    GLP Receptor Metabolic Disease
    GZR18 is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC50 of 0.677 nM. GZR18 ameliorates type 2 diabetes [1].
  • HY-13443R

    GCGR Metabolic Disease
    Exendin-4 (Standard) is the analytical standard of Exendin-4. This product is intended for research and analytical applications. Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-P0014S2

    Isotope-Labeled Compounds Others
    Liraglutide- 13C6, 15N (TFA)is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus [1].
  • HY-114118R

    GCGR Metabolic Disease
    Semaglutide (Standard) is the analytical standard of Semaglutide. This product is intended for research and analytical applications. Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
  • HY-P0014S1

    Isotope-Labeled Compounds Others
    Liraglutide- 13C5, 15N (tetraTFA)is the 13C and 15N labeledLiraglutide(HY-P0014) [1]. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .
  • HY-P1731B
    Tirzepatide hydrochloride
    3 Publications Verification

    LY3298176 hydrochloride

    GLP Receptor Neurological Disease Metabolic Disease Cancer
    Tirzepatide hydrochloride (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide hydrochloride has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity [1] .
  • HY-P1731
    Tirzepatide
    3 Publications Verification

    LY3298176

    GLP Receptor Neurological Disease Metabolic Disease Cancer
    Tirzepatide (LY3298176) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity [1] .
  • HY-P1731A

    LY3298176 TFA

    GLP Receptor Neurological Disease Metabolic Disease Cancer
    Tirzepatide TFA (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide TFA has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity [1] .
  • HY-P3291

    ZP7570

    GCGR Metabolic Disease
    Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide can be used for short bowel syndrome (SBS) research [1].

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: